Who is sponsoring NCT04057053?

NCT04057053 is sponsored by Massachusetts Eye and Ear Infirmary.

What drugs are being tested in NCT04057053?

Interventions in NCT04057053: Netarsudil 0.02% Ophthalmic Solution.

What condition does NCT04057053 study?

NCT04057053 studies Fuchs' Endothelial Dystrophy, Cataract.

Is NCT04057053 still recruiting?

NCT04057053 is currently completed. Last updated 26 January 2021.

Last reviewed 2021-01-26 · How we verify

NCT04057053

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty

Completed EARLY_PHASE1 Last updated 26 January 2021

What this trial tests

EARLY_PHASE1 trial testing Netarsudil 0.02% Ophthalmic Solution in Fuchs' Endothelial Dystrophy in 10 participants. Completed in 20 December 2020.

Timeline

2 October 2018

Primary endpoint
20 December 2020

20 December 2020

Quick facts

Lead sponsor	Massachusetts Eye and Ear Infirmary
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	2 October 2018
Primary completion	20 December 2020
Estimated completion	20 December 2020
Sites	1 location across United States

Drugs / interventions tested

Netarsudil 0.02% Ophthalmic Solution — full drug profile →

Conditions studied

Fuchs' Endothelial Dystrophy — all drugs for Fuchs' Endothelial Dystrophy →
Cataract — all drugs for Cataract →

Sponsor

Massachusetts Eye and Ear Infirmary — full company profile →

Who can join

Adults 50 to 70, any sex, with Fuchs' Endothelial Dystrophy or Cataract. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary aim of the study is to determine whether a rho kinase inhibitor, Netarsudil, can speed corneal clearance after DWEK. Secondary aim of the study is to investigate whether patient factors, such as baseline age, pachymetry, or endothelial cell count influence response to Netarsudil.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Rho-Kinase as a Target for Cancer Therapy and Its Immunotherapeutic Potential.
Kim S, Kim SA, Han J, Kim IS. · · 2021 · cited 50× · PMID 34884721 · DOI 10.3390/ijms222312916
Therapeutic future of Fuchs endothelial corneal dystrophy: An ongoing way to explore.
Liu JX, Chiang TL, Hung KF, Sun YC. · · 2024 · cited 5× · PMID 38654984 · DOI 10.4103/tjo.tjo-d-23-00115

Verify or expand the search:

Other trials of Netarsudil 0.02% Ophthalmic Solution

Trials testing the same drug.

NCT06969586 — The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy · enrolling by invitation
NCT06441643 — Next Generation Rocklatan · Phase 2 · completed

Other recruiting trials for Fuchs' Endothelial Dystrophy

Currently open trials in the same condition.

NCT06261346 — Plasma Rich in Growth Factors in Corneal Endothelial Transplantation · NA · recruiting
NCT06881771 — FECD-TRACE: Fuchs' Endothelial Corneal Dystrophy TRAjectory and Correlation With Genotype in the United Kingdom · recruiting
NCT05275972 — Descemet Endothelial Thickness Comparison Trial II · Phase 3 · recruiting
NCT05636579 — Study to Assess Safety and Tolerability of Multiple Doses of EO2002 · Phase 1 · recruiting
NCT05436665 — The Belgian Endothelial Surgical Transplant of the Cornea · NA · recruiting

Other Massachusetts Eye and Ear Infirmary trials

Trials by the same sponsor.

NCT06926478 — Subconjunctival Humira for Boston Keratoprosthesis · Phase 1 · not yet recruiting
NCT06425419 — The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy · Phase 1 · not yet recruiting
NCT07383701 — Lactiplantibacillus Plantarum 299v Probiotic Supplementation in Patients With Diabetic Macular Edema · Phase 2 · not yet recruiting
NCT06688578 — Testing Effectiveness of a Stochastic Noise Stimulator to Immediately Improve Balance and Gait · NA · recruiting
NCT06753916 — ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04057053 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts Eye and Ear Infirmary
Last refreshed: 26 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04057053.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing